Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation
Identifieur interne : 005F10 ( Ncbi/Merge ); précédent : 005F09; suivant : 005F11Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation
Auteurs : Gajalakshmi Dakshinamoorthy ; Ramaswamy KalyanasundaramSource :
- Vaccine [ 0264-410X ] ; 2013.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques, Animaux, Anticorps antihelminthe (immunologie), Anticorps antihelminthe (sang), Antigènes d'helminthe (immunologie), Brugia malayi (génétique), Brugia malayi (immunologie), Filariose lymphatique (), Filariose lymphatique (immunologie), Immunisation, Immunoglobuline G (immunologie), Immunoglobuline G (sang), Modèles animaux de maladie humaine, Mâle, Protéines d'helminthes (génétique), Protéines d'helminthes (immunologie), Rate (immunologie), Souris, Spécificité des anticorps (immunologie), Vaccins (administration et posologie), Vaccins (immunologie).
- MESH :
- administration et posologie : Vaccins.
- génétique : Brugia malayi, Protéines d'helminthes.
- immunologie : Anticorps antihelminthe, Antigènes d'helminthe, Brugia malayi, Filariose lymphatique, Immunoglobuline G, Protéines d'helminthes, Rate, Spécificité des anticorps, Vaccins.
- sang : Anticorps antihelminthe, Immunoglobuline G.
- Adjuvants immunologiques, Animaux, Filariose lymphatique, Immunisation, Modèles animaux de maladie humaine, Mâle, Souris.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Animals, Antibodies, Helminth (blood), Antibodies, Helminth (immunology), Antibody Specificity (immunology), Antigens, Helminth (immunology), Brugia malayi (genetics), Brugia malayi (immunology), Disease Models, Animal, Elephantiasis, Filarial (immunology), Elephantiasis, Filarial (prevention & control), Helminth Proteins (genetics), Helminth Proteins (immunology), Immunization, Immunoglobulin G (blood), Immunoglobulin G (immunology), Male, Mice, Spleen (immunology), Vaccines (administration & dosage), Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines.
- chemical , blood : Antibodies, Helminth, Immunoglobulin G.
- chemical , genetics : Helminth Proteins.
- chemical , immunology : Antibodies, Helminth, Antigens, Helminth, Helminth Proteins, Immunoglobulin G, Vaccines.
- chemical : Adjuvants, Immunologic.
- genetics : Brugia malayi.
- immunology : Antibody Specificity, Brugia malayi, Elephantiasis, Filarial, Spleen.
- prevention & control : Elephantiasis, Filarial.
- Animals, Disease Models, Animal, Immunization, Male, Mice.
Abstract
Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; r
Url:
DOI: 10.1016/j.vaccine.2013.10.083
PubMed: 24211167
PubMed Central: 3866973
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 003798
- to stream Pmc, to step Curation: 003797
- to stream Pmc, to step Checkpoint: 002347
- to stream PubMed, to step Corpus: 001848
- to stream PubMed, to step Curation: 001848
- to stream PubMed, to step Checkpoint: 001848
Links to Exploration step
PMC:3866973Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating the efficacy of r<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24211167</idno>
<idno type="pmc">3866973</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866973</idno>
<idno type="RBID">PMC:3866973</idno>
<idno type="doi">10.1016/j.vaccine.2013.10.083</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">003798</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003798</idno>
<idno type="wicri:Area/Pmc/Curation">003797</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003797</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002347</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002347</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001848</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001848</idno>
<idno type="wicri:Area/PubMed/Curation">001848</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001848</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001848</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001848</idno>
<idno type="wicri:Area/Ncbi/Merge">005F10</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluating the efficacy of r<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Antibodies, Helminth (blood)</term>
<term>Antibodies, Helminth (immunology)</term>
<term>Antibody Specificity (immunology)</term>
<term>Antigens, Helminth (immunology)</term>
<term>Brugia malayi (genetics)</term>
<term>Brugia malayi (immunology)</term>
<term>Disease Models, Animal</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Helminth Proteins (genetics)</term>
<term>Helminth Proteins (immunology)</term>
<term>Immunization</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Male</term>
<term>Mice</term>
<term>Spleen (immunology)</term>
<term>Vaccines (administration & dosage)</term>
<term>Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Anticorps antihelminthe (immunologie)</term>
<term>Anticorps antihelminthe (sang)</term>
<term>Antigènes d'helminthe (immunologie)</term>
<term>Brugia malayi (génétique)</term>
<term>Brugia malayi (immunologie)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (immunologie)</term>
<term>Immunisation</term>
<term>Immunoglobuline G (immunologie)</term>
<term>Immunoglobuline G (sang)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Protéines d'helminthes (génétique)</term>
<term>Protéines d'helminthes (immunologie)</term>
<term>Rate (immunologie)</term>
<term>Souris</term>
<term>Spécificité des anticorps (immunologie)</term>
<term>Vaccins (administration et posologie)</term>
<term>Vaccins (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Helminth Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Antigens, Helminth</term>
<term>Helminth Proteins</term>
<term>Immunoglobulin G</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Brugia malayi</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Brugia malayi</term>
<term>Protéines d'helminthes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Antigènes d'helminthe</term>
<term>Brugia malayi</term>
<term>Filariose lymphatique</term>
<term>Immunoglobuline G</term>
<term>Protéines d'helminthes</term>
<term>Rate</term>
<term>Spécificité des anticorps</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Specificity</term>
<term>Brugia malayi</term>
<term>Elephantiasis, Filarial</term>
<term>Spleen</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Immunization</term>
<term>Male</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Filariose lymphatique</term>
<term>Immunisation</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; r<italic>Bm</italic>
HSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), r<italic>Bm</italic>
ALT-2 (Abundant larval transcript) and r<italic>Bm</italic>
TSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (r<italic>Bm</italic>
HATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of r<italic>Bm</italic>
HATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with r<italic>Bm</italic>
HATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent <italic>in vivo</italic>
challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the r<italic>Bm</italic>
HATαc vaccine against <italic>B. malayi</italic>
L3 in mice.</p>
</div>
</front>
</TEI>
<double pmid="24211167"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating the efficacy of r<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24211167</idno>
<idno type="pmc">3866973</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866973</idno>
<idno type="RBID">PMC:3866973</idno>
<idno type="doi">10.1016/j.vaccine.2013.10.083</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">003798</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003798</idno>
<idno type="wicri:Area/Pmc/Curation">003797</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003797</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002347</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002347</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluating the efficacy of r<italic>Bm</italic>
HATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; r<italic>Bm</italic>
HSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), r<italic>Bm</italic>
ALT-2 (Abundant larval transcript) and r<italic>Bm</italic>
TSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (r<italic>Bm</italic>
HATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of r<italic>Bm</italic>
HATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with r<italic>Bm</italic>
HATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent <italic>in vivo</italic>
challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the r<italic>Bm</italic>
HATαc vaccine against <italic>B. malayi</italic>
L3 in mice.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA. Electronic address: ramswamy@uic.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:24211167</idno>
<idno type="pmid">24211167</idno>
<idno type="doi">10.1016/j.vaccine.2013.10.083</idno>
<idno type="wicri:Area/PubMed/Corpus">001848</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001848</idno>
<idno type="wicri:Area/PubMed/Curation">001848</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001848</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001848</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001848</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.</title>
<author><name sortKey="Dakshinamoorthy, Gajalakshmi" sort="Dakshinamoorthy, Gajalakshmi" uniqKey="Dakshinamoorthy G" first="Gajalakshmi" last="Dakshinamoorthy">Gajalakshmi Dakshinamoorthy</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kalyanasundaram, Ramaswamy" sort="Kalyanasundaram, Ramaswamy" uniqKey="Kalyanasundaram R" first="Ramaswamy" last="Kalyanasundaram">Ramaswamy Kalyanasundaram</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107, USA. Electronic address: ramswamy@uic.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Animals</term>
<term>Antibodies, Helminth (blood)</term>
<term>Antibodies, Helminth (immunology)</term>
<term>Antibody Specificity (immunology)</term>
<term>Antigens, Helminth (immunology)</term>
<term>Brugia malayi (genetics)</term>
<term>Brugia malayi (immunology)</term>
<term>Disease Models, Animal</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Helminth Proteins (genetics)</term>
<term>Helminth Proteins (immunology)</term>
<term>Immunization</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Male</term>
<term>Mice</term>
<term>Spleen (immunology)</term>
<term>Vaccines (administration & dosage)</term>
<term>Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Anticorps antihelminthe (immunologie)</term>
<term>Anticorps antihelminthe (sang)</term>
<term>Antigènes d'helminthe (immunologie)</term>
<term>Brugia malayi (génétique)</term>
<term>Brugia malayi (immunologie)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (immunologie)</term>
<term>Immunisation</term>
<term>Immunoglobuline G (immunologie)</term>
<term>Immunoglobuline G (sang)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Protéines d'helminthes (génétique)</term>
<term>Protéines d'helminthes (immunologie)</term>
<term>Rate (immunologie)</term>
<term>Souris</term>
<term>Spécificité des anticorps (immunologie)</term>
<term>Vaccins (administration et posologie)</term>
<term>Vaccins (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Helminth Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Antigens, Helminth</term>
<term>Helminth Proteins</term>
<term>Immunoglobulin G</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Brugia malayi</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Brugia malayi</term>
<term>Protéines d'helminthes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Antigènes d'helminthe</term>
<term>Brugia malayi</term>
<term>Filariose lymphatique</term>
<term>Immunoglobuline G</term>
<term>Protéines d'helminthes</term>
<term>Rate</term>
<term>Spécificité des anticorps</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Specificity</term>
<term>Brugia malayi</term>
<term>Elephantiasis, Filarial</term>
<term>Spleen</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Immunization</term>
<term>Male</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Animaux</term>
<term>Filariose lymphatique</term>
<term>Immunisation</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Developing an effective vaccine against lymphatic filariasis will complement the WHO's effort to eradicate the infection from endemic areas. Currently 83 different countries are endemic for this infection and over 1 billion people are at risk. An effective vaccine coupled with mass drug administration will reduce the morbidity and social stigma associated with this gruesome disease. Several potential vaccine candidates that can confer partial protection in experimental animals have been reported from different laboratories. However, no licensed vaccines are currently available for this disease. Among the several vaccine antigens identified from our laboratory, three most promising antigens; rBmHSPαc (α crystalline domain and c-terminal extension of Heat Shock Protein 12.6), rBmALT-2 (Abundant larval transcript) and rBmTSP LEL (Tetraspanin large extracellular loop) was further developed as a recombinant fusion protein vaccine (rBmHATαc). In a mouse model this fusion protein vaccine gave close to 68% protection following a challenge infection. To improve the vaccine efficiency of rBmHATαc, in this study we evaluated various preparations of alum (AL007, AL019, Alhydrogel and Imject® Alum) as adjuvants. Our results show that mice immunized with rBmHATαc formulated in AL007 (alum from IDRI) and/or AL019 (alum plus TLR-4 agonist from IDRI) gave the highest IgG antibody titer compared to other groups. Subsequent in vivo challenge experiments confirmed that >95% protection can be achieved when AL007 or AL019 was used as the adjuvant. However, when Imject® Alum or alhydrogel was used as the adjuvant only 76% and 72% protection respectively could be achieved. These results show that AL007 or AL019 (IDRI) is an excellent choice of adjuvant for the rBmHATαc vaccine against B. malayi L3 in mice.</div>
</front>
</TEI>
</pubmed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005F10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 005F10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:3866973 |texte= Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24211167" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |